We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

WD:NYSEWalker & Dunlop, Inc Analysis

Data as of 2026-06-06 - not real-time

$51.25

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Walker & Dunlop delivered a strong Q1 with sales up 26.9% YoY to $301.3 million and non‑GAAP EPS of $1.02, nearly 90% ahead of consensus, reinforcing its revenue growth momentum. Operating margins expanded to roughly 9% and profit margins to 5.7%, while the Capital Markets segment’s share of revenue fell from 84% to 68%, indicating improving operating leverage as loan volumes recover. However, the balance sheet remains strained: total debt exceeds $3.4 billion, driving a debt‑to‑equity ratio above 200%, and operating cash flow is deeply negative, raising concerns about cash sustainability. The stock trades at a forward P/E of under 9× earnings and a price‑to‑book below 1.0, suggesting a potential valuation edge, yet the current dividend yield of over 5% is backed by a payout ratio above 130%, which is unlikely to be sustainable.
Technical indicators are mixed; the price sits just above the 20‑day SMA and is neutral on the RSI, but the MACD histogram is bearish and volume is trending down, reflecting short‑term pressure. Volatility remains high at roughly 40% over the past month and beta is above 1, implying heightened market sensitivity. Given the upside potential implied by analyst targets (≈34% from current levels) but balanced against leverage, cash‑flow deficits, and dividend risk, the stock appears fairly valued with a blend of growth and value characteristics, warranting a cautious but optimistic stance.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD and decreasing volume signal near‑term pressure
  • Recent earnings beat provides short‑term support
  • Proximity to support level around $47.4

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong revenue growth and expanding margins
  • Forward P/E below 9× and price‑to‑book under 1.0 indicate valuation upside
  • Analyst price targets suggest ~34% upside

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • High leverage and negative operating cash flow constrain long‑run flexibility
  • Unsustainable dividend payout raises sustainability concerns
  • Book value exceeds market price, offering a margin of safety

Key Metrics & Analysis

Financial Health

Revenue Growth32.00%
Profit Margin5.72%
P/E Ratio25.4
ROE4.15%
ROA1.35%
Debt/Equity201.54
P/B Ratio1.0
Op. Cash Flow$-1527113984
Industry P/E17.0

Technical Analysis

TrendNeutral
RSI52.5
Support$47.37
Resistance$55.51
MA 20$51.10
MA 50$49.51
MA 200$63.73
MACDBearish
VolumeDecreasing
Fear & Greed Index83.02

Valuation

Target Price$68.67
Upside/Downside33.98%
GradeFair
TypeBlend
Dividend Yield5.31%

Risk Assessment

Beta1.20
Volatility40.02%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.